Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
JP Morgan assesses the specialty pharma sector, highlighting robust fundamentals and new product excitement. Key focus on Teva,...
https://truthsocial.com/@realDonaldTrump/posts/113012083325505976
Fiscal Year 2024 Outlook: Company updates its fiscal 2024 organic net sales growth outlook versus the prior year to -3% to -...
Perrigo (NYSE:PRGO) reported quarterly earnings of $0.53 per share which beat the analyst consensus estimate of $0.51 by 3.92 p...
AbbVie petitions the U.S. Supreme Court to protect its corporate records, arguing a lower court ruling threatens attorney-clien...
Piper Sandler analyst Korinne Wolfmeyer maintains Perrigo (NYSE:PRGO) with a Overweight and lowers the price target from $36...
- Reuters
- Reuters
- Reuters Citing Bloomberg Reporter On X, Citing Copy Of Opinion Briefly Posted On Court's Website
